JO
CLRB icon

John Overdeck’s Cellectar Biosciences CLRB Stock Holding History

John Overdeck’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,770
Closed -$26.2K – 3225
2025
Q1 		$26.2K Buy
2,770
+399
+17% +$3.61K ﹤0.01% 3088
2024
Q4 		$21.3K Buy
+2,371
New +$110K ﹤0.01% 3103
2024
Q2 		– Sell
-674
Closed -$80.5K – 3069
2024
Q1 		$80.5K Buy
+674
New +$73K ﹤0.01% 2850
2022
Q1 		– Sell
-217
Closed -$43K – 2936
2021
Q4 		$43K Buy
217
+62
+40% +$14.9K ﹤0.01% 4147
2021
Q3 		$43K Sell
155
-701
-82% -$214K ﹤0.01% 4154
2021
Q2 		$306K Sell
856
-1,355
-61% -$588K ﹤0.01% 3500
2021
Q1 		$1.07M Buy
2,211
+2,054
+1,308% +$1.22M ﹤0.01% 2251
2020
Q4 		$98K Buy
+157
New +$72.2K ﹤0.01% 3214

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

John Overdeck's CLRB Position: Q2 2025 in Review

John Overdeck sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 2,770 shares — an estimated $26.2K sold.

John Overdeck first reported a position in CLRB in Q4 2020 and held it in 8 quarters. The position peaked at $1.07M in Q1 2021. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • John Overdeck reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • John Overdeck sold 2,770 Cellectar Biosciences shares in Q2 2025, an estimated $26.2K.
  • John Overdeck first reported a position in Cellectar Biosciences in Q4 2020 and held it in 8 quarters.
  • John Overdeck's Cellectar Biosciences position peaked at $1.07M in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on Two Sigma Investments's 13F filing for Q2 2025, filed 14 Aug 2025.